Livmarli
Maralixibat chloride
Alagille Syndrome
Date of authorisation:
Revision: 5
Last updated:
MedicineHumanAuthorised
EMEA-001475-PIP03-17-M03 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Gastroentology-Hepatology
PIP number: P/0436/2022
Route(s) of administration: Oral use
Pharmaceutical form(s):
Oral solution
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Lumigan
bimatoprost
Glaucoma, Open-Angle
Ocular Hypertension
Date of authorisation:
Revision: 37
Last updated:
MedicineHumanAuthorised
Livmarli
maralixibat
Date of withdrawal:
Last updated:
MedicineHumanWithdrawn application
EMEA-000917-PIP01-10-M04 - paediatric investigation plan
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Dermatology
PIP number: P/0293/2014
Route(s) of administration: Ocular useCutaneous useIntraocular use
Pharmaceutical form(s):
Eye drops, solution
Cutaneous solution
Ophthalmic insert
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
EMEA-000917-PIP02-11 - paediatric investigation plan
Decision type: P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
Therapeutic area: Dermatology
PIP number: P/0089/2012
Route(s) of administration: Cutaneous use
Pharmaceutical form(s):
Cutaneous solution
Decision date:
Last updated:
Compliance check: ✖
PIPHuman